Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye

NCT05848128 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

642

Enrollment

INDUSTRY

Sponsor class

Conditions

Dry Eye Syndromes
Dry Eye Disease
Kerato Conjunctivitis Sicca

Interventions

DRUG: 5% Tavilermide ophthalmic solution
OTHER: Vehicle ophthalmic solution

Sponsor

Mimetogen Pharmaceuticals USA, Inc.